Tetteh, Ebenezer K.; Morris, Stephen - In: Health Economics Review 4 (2014) 26, pp. 1-16
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to...